Notice of Special Interest (NOSI): Long-Term Neurocognitive Consequences of COVID-19 in Individuals Living with HIV and Substance Use Disorders
This notice applies to due dates on or after May 7, 2021 and subsequent receipt dates through September 7, 2024.
NIDA is interested in receiving research applications focusing on studying the long-term neurocognitive consequences of the COVID-19/HIV/SUDs syndemic.
This NOSI encourages, but is not limited to, research applications in the following areas:
- Long-term neurocognitive effects of HIV/COVID-19/SUDs. Basic science studies to explore changes in neuroanatomy, neurophysiology, biochemistry, learning and behavior.
- Clinical studies to evaluate cognitive, behavioral, neuropsychiatric, neuro-therapeutic outcomes, etc. Staging and categorizing of cognitive dysfunction. Differentiation between HAND and COVID-19 neurocognitive impairment in individuals with and without SUDs. Validation of neurocognitive scales for HAND and COVI-19 neurocognitive impairment.
- Neurocognitive studies in individuals with HIV/COVID-19/SUDs classified by age/gender/race/socioeconomic status/drug of choice use/ART regime/HCV status/other co-morbidities/criminal justice involvement, etc.
- Therapeutic strategies for such neurocognitive dysfunction in the context of HIV. Effectiveness of NMDA receptor antagonists, Anticholinergics, B12 supplements, Thiamine, SSRI’s, Benzodiazepines, Antipsychotics, etc., and its interactions with ART and SUDs. Cognitive Behavioral Therapy; Mindfulness; Meditation; Transcranial Magnetic Stimulation and others.
Notice of Special Interest (NOSI): Medical Consequences of Smoking and Vaping Drugs of Abuse in Individuals with HIV and COVID-19
This notice applies to due dates on or after May 5, 2021 and subsequent receipt dates through September 7, 2024.
Research Objectives: NIDA is interested in receiving research applications focusing on individuals with HIV who smoke or vape marijuana, tobacco, cocaine and/or methamphetamine to determine the long-term effects of their use among individuals with HIV and COVID-19.
The risks that smoking and/or vaping tobacco, marijuana, cocaine, and/or methamphetamine may have on acquiring the SARS-CoV2 infection in individuals with HIV.
The medical consequences, co-morbidity, and complications of SARS-CoV2 infection affecting cardiovascular, respiratory, renal, gastrointestinal, hematological, immunological, CNS and PNS systems in HIV individuals who smoke and/or vape tobacco, marijuana, cocaine, and/or methamphetamine.
Defining mechanisms by which substance use and HIV interact to increase susceptibility to severe COVID-19 affecting cardiovascular, respiratory, renal, gastrointestinal, hematological, immunological, CNS and PNS morbidity.
Utilization of large database- Electronic Health Records – strategies for retrospective and platform based prospective studies, cross analyses, and real-time health delivery and critical health-related decisions in emergency medicine settings.
Investigators are encouraged to make use of existing data sets and resources.
Notice of Special Interest (NOSI): Administrative Supplements for the Clinical and Translational Science Award (CTSA) Program to Address COVID-19 Public Health Needs
Applications will be accepted immediately and on a rolling basis through August 16, 2024 by 5:00 PM local time.
The parent award must be active when the supplement application is submitted (e.g. within the originally reviewed and approved project period). The research proposed in the supplement should be requested for one year and should be accomplished within the currently approved project period for the existing parent award.
The project period will generally be limited to 1 year. Project periods up to 2 years will be considered only with strong justification.
The NCATS may consider on a case-by-case basis a no-cost extension for the supplement of up to an additional year at the conclusion of the first year, provided it is well justified and within the remaining parent project period.
Notice of Special Interest (NOSI): Administrative Supplement Opportunity to Study the Impact of COVID-19 on Global Cancer Prevention and Control
First Available Due Date: March 31, 2021
This Notice of Special Interest (NOSI) informs current awardees that the National Cancer Institute (NCI) is providing the opportunity for supplemental funding to stimulate interest and promote studies on the impact of the COVID-19 pandemic on global cancer prevention and control. This Administrative Supplement is designed to support NCI-funded investigators who have existing relationships/partnerships in low- and middle-income countries (LMICs), inclusive of upper-middle-income countries, to leverage those partnerships to conduct research on the pandemic’s impact on cancer prevention, diagnosis, treatment, and outcomes.
Notice of Special Interest: Administrative Supplements for COVID-19 Impacted NIMH Research
This notice applies to due dates on or after January 5, 2021 with rolling receipt through June 1, 2023.
The purpose of this Notice is to outline priorities for providing supplemental funding to investigators and institutions with active National Institute of Mental Health (NIMH) awards that have been significantly impacted by the COVID-19 pandemic.
Notice of Special Interest (NOSI): NIA Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19)
First Available Due Date: April 06, 2020
NIA is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on Coronavirus Disease 2019 (COVID-19). The mission of NIA is to support and conduct genetic, biological, clinical, behavioral, social, and economic research on aging. This NOSI supports mission critical areas of research for NIA as they relate to the COVID-19 pandemic.
Notice of Intent to Publish a Funding Opportunity Announcement for SARS-CoV-2, COVID-19 and Consequences of Alcohol Use (R03 Clinical Trials Not Allowed)
Estimated Post Date: February 15, 2021
Notice of Intent to Publish a Funding Opportunity Announcement for SARS-CoV-2, COVID-19 and Consequences of Alcohol Use (R21 Clinical Trials Not Allowed)
Estimated Post Date: February 15, 2021